全文获取类型
收费全文 | 475篇 |
免费 | 23篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 44篇 |
妇产科学 | 7篇 |
基础医学 | 45篇 |
口腔科学 | 5篇 |
临床医学 | 53篇 |
内科学 | 54篇 |
皮肤病学 | 11篇 |
神经病学 | 14篇 |
特种医学 | 98篇 |
外科学 | 90篇 |
综合类 | 6篇 |
预防医学 | 22篇 |
眼科学 | 2篇 |
药学 | 31篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 6篇 |
2021年 | 8篇 |
2019年 | 8篇 |
2018年 | 4篇 |
2017年 | 5篇 |
2016年 | 3篇 |
2015年 | 6篇 |
2014年 | 10篇 |
2013年 | 5篇 |
2012年 | 14篇 |
2011年 | 10篇 |
2010年 | 23篇 |
2009年 | 13篇 |
2008年 | 18篇 |
2007年 | 21篇 |
2006年 | 18篇 |
2005年 | 17篇 |
2004年 | 11篇 |
2003年 | 13篇 |
2002年 | 10篇 |
2001年 | 7篇 |
2000年 | 4篇 |
1998年 | 20篇 |
1997年 | 21篇 |
1996年 | 13篇 |
1995年 | 11篇 |
1994年 | 14篇 |
1993年 | 15篇 |
1992年 | 7篇 |
1991年 | 10篇 |
1990年 | 6篇 |
1989年 | 12篇 |
1988年 | 14篇 |
1987年 | 9篇 |
1986年 | 16篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 3篇 |
1982年 | 9篇 |
1981年 | 3篇 |
1980年 | 8篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1976年 | 11篇 |
1975年 | 9篇 |
1974年 | 3篇 |
1973年 | 5篇 |
1972年 | 3篇 |
1967年 | 2篇 |
排序方式: 共有506条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
RM Nobre ALR Ribeiro SM Alves-Junior FM Tuji M das G Rodrigues Pinheiro LR Pinheiro JJV Pinheiro 《Dento maxillo facial radiology》2012,41(7):541-547
Objectives
A wide variety of manifestations is presented in patients with Gaucher''s disease (GD), including bone, haematology and visceral disturbances. This study was conducted to ascertain the main maxillofacial abnormalities by means of clinical survey, panoramic and cone beam CT (CBCT); to compare the patient''s group with an age–sex matched control group; and to correlate clinical and radiological data.Methods
Ten patients previously diagnosed with GD were submitted to clinical and radiological surveys (CBCT and panoramic radiographs). The examination consisted of anamnesis, extra- and intraoral examinations and analyses of each patient''s records. Imaging data were collected from the point of view of 3 observers, and the results compared with a healthy group (20 individuals) by means of statistical analysis (Fisher''s exact test).Results
Gaucher patients had significantly more manifestations than otherwise healthy carriers. The most prevalent findings were enlarged marrow spaces, generalized osteopenia and effacement of jaw structures (mandibular canal, lamina dura and mental foramen). Here we describe a case in which thickening of the maxillary sinus mucosa was observed on CBCT rather than opacification of the sinus as seen on panoramic radiographs. Pathological fractures, root resorption and delay on tooth eruption were not observed.Conclusions
A poor relationship could be observed between clinical and radiological data. Patients showed important bone manifestations, which require careful diagnostic and surgical planning whenever necessary. Although panoramic radiographs have shown significant differences, CBCT is more effective in pointing out differences between patients and a control group, thus showing it as an important tool for evaluation of Gaucher patients. 相似文献55.
56.
Mitchell PL; Clutterbuck RD; Powles RL; De Lord C; Morilla R; Hiorns LR; Titley J; Catovsky D; Millar JL 《Blood》1996,87(11):4797-4803
Human interleukin-4 (huIL-4) has been shown to inhibit the growth in vitro of cells from patients with acute lymphoblastic leukemia (ALL). With the aim of determining whether this cytokine might be useful in the treatment of patients with ALL, the effects of huIL-4 on human B- cell precursor ALL engrafted in severe combined immunodeficient (SCID) mice were examined. The inhibition of [3H] thymidine uptake of primary ALL cells by huIL-4 was maintained following engraftment and passage of leukemia in SCID mice. Five of seven xenograft leukemias showed significant inhibition in vitro by huIL-4 at concentrations as low as 0.5 ng/mL; furthermore, huIL-4 counteracted the proliferative effects of IL-7. When used to treat two human leukemias engrafted in SCID mice, huIL-4 200 microgram/kg/d, as a continuous 14-day subcutaneous infusion, suppressed the appearance of circulating lymphoblasts and extended survival of mice by 39% and 108%, respectively, the first demonstration of IL-4 activity against human leukemia in vivo. The mean steady-state huIL-4 level in mouse plasma during the infusion was 1.46 ng/mL (SEM +/- 0.14 ng/mL), which was similar to concentrations found to be effective in vitro. ALL cells obtained from mice relapsing after huIL-4 treatment continued to show inhibition by the cytokine in vitro. These data suggest that IL-4 may be useful in the treatment of patients with ALL. 相似文献
57.
Pretreatment hematocrit in 117 advanced-stage Hodgkin's disease patients treated with a combined modality therapy program was evaluated as an independent prognostic variable with regard to survival and relapse-free survival. Age greater than 40 years, and multiple extranodal sites of involvement were found to be statistically significant independent negative prognostic factors with regard to survival. Pretreatment hematocrit, however, was not an independent negative prognostic variable. 相似文献
58.
59.
60.
Molly B. Moravek Leslie C. Appiah Antoinette Anazodo Karen C. Burns Veronica Gomez-Lobo Holly R. Hoefgen Olivia Jaworek Frias Monica M. Laronda Jennifer Levine Lillian R. Meacham Mary Ellen Pavone Gwendolyn P. Quinn Erin E. Rowell Andrew C. Strine Teresa K. Woodruff Leena Nahata 《The Journal of adolescent health》2019,64(5):563-573
Infertility is known to decrease quality of life among adults. In some cases, infertility is caused by medical conditions and/or treatments prescribed in childhood, and using methods to protect or preserve fertility may expand future reproductive possibilities. Structured programs to offer counseling about infertility risk and fertility preservation options are essential in the care of pediatric patients facing fertility-threatening conditions or treatments, yet multiple barriers to program development exist. This report was developed from the institutional experiences of members of the Pediatric Initiative Network of the Oncofertility Consortium, with the intent of providing guidance for health care providers aiming to establish programs at institutions lacking pediatric fertility preservation services. The mechanics of building a fertility preservation program are discussed, including essential team members, target populations, fertility preservation options (both established and experimental), survivorship issues, research opportunities, and ethical considerations. Common barriers to program development and utilization, including low referral rates and financial concerns, are also discussed, and recommendations made for overcoming such barriers. 相似文献